Method and kit for determining benefit of chemotherapy
AssigneeSt. Jude Children's Research Hospital
InventorsJun J. Yang, Jiyang Yu
Life of this patent
Estimating the term…
Abstract
Nucleic acid- and protein-based methods for identifying a patient sensitive to treatment with a tyrosine kinase inhibitor are provided, as is a method for treating a subject with a T-lineage hematological malignancy. Specifically, the method comprising determining activity levels of LCK nucleic acid or protein in a biological sample from a patient with a T-lineage hematological malignancy, wherein an increase in the activity levels of the LCK nucleic acid or protein in the biological sampled compared to a reference level indicates that the patient is sensitive to treatment with a tyrosine kinase inhibitor.
Claims6
A method of identifying and treating a patient sensitive to treatment with a tyrosine kinase inhibitor comprising
- determining increased activity levels of LCK nucleic acid or protein in a biological sample isolated from a patient with a T-lineage hematological malignancy as compared to a reference level in combination with
- determining an increased activity level of CD28, CD3E, CD40LG, CD3G, ICOS, and/or PTCRA nucleic acids as compared to a reference level, and
- treating the patient exhibiting increases in the activity levels of the LCK nucleic acid or protein and an increase in the activity level of CD28, CD3E, CD40LG, CD3G, ICOS, and/or PTCRA nucleic acids as compared to reference levels with a tyrosine kinase inhibitor, thereby identifying and treating the patient sensitive to treatment with a tyrosine kinase inhibitor.
Dependencies are inferred from the claim text.